$3.76-0.25 (-6.12%)
Chiasma, Inc. (CHMA) is a Major Pharmaceuticals company listed on NASDAQ. There were no new wire items for CHMA in the last 30 days. The most recent was published Nov 3, 2022.
Latest news
25 items- PRAmryt Reports Q3 2022 Financial and Operational ResultsAmryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26
- PRAmryt Reports Record Q2 2022 ResultsAmryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway
- PRSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive OfficerNovel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o
- PRAmryt Reports Record Q1 2022 ResultsAmryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c
- PRAmryt Announces 22% growth in FY 2021 Revenues to $222.5MAmryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing 17%-21% YoY growth Cash of $113.0M at December 31, 2021 Board approves stock repurchase program of up to $30M 8th consecutive quarter of positive EBITDA generation 32% YoY growth in metreleptin revenues Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Global NET market opportunity is estimated to be approx. $1.9bn* Conference call and webcast today at 0830 EST / 1330 GMT DUBLIN, Ireland, and Boston MA, March 9, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring
- SECSEC Form EFFECT filed by Chiasma, Inc.EFFECT - CHIASMA, INC (0001339469) (Filer)
- SECSEC Form 15-12B filed by Chiasma, Inc.15-12B - CHIASMA, INC (0001339469) (Filer)
- INSIDERSEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company4 - CHIASMA, INC (0001339469) (Issuer)
- 13D/GSEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)SC 13G/A - CHIASMA, INC (0001339469) (Subject)
- SECSEC Form S-8 POS filed by Chiasma, Inc.S-8 POS - CHIASMA, INC (0001339469) (Filer)
- SECSEC Form S-8 POS filed by Chiasma, Inc.S-8 POS - CHIASMA, INC (0001339469) (Filer)
- SECSEC Form S-8 POS filed by Chiasma, Inc.S-8 POS - CHIASMA, INC (0001339469) (Filer)
- SECSEC Form S-8 POS filed by Chiasma, Inc.S-8 POS - CHIASMA, INC (0001339469) (Filer)
- SECSEC Form S-8 POS filed by Chiasma, Inc.S-8 POS - CHIASMA, INC (0001339469) (Filer)
- SECSEC Form POS AM filed by Chiasma, Inc.POS AM - CHIASMA, INC (0001339469) (Filer)
- INSIDERSEC Form 4: LUDLAM WILLIAM returned 11,799 units of Common Stock to the company, closing all direct ownership in the company4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4 filed by Mamluk Roni4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4: Minick Scott returned 149,725 units of Common Stock to the company, closing all direct ownership in the company4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4: SCARLETT JOHN A returned 61,322 units of Common Stock to the company, closing all direct ownership in the company4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4: STACK DAVID M returned 25,000 units of Common Stock to the company4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4 filed by THERO JOHN F4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4 filed by Varadan Anand4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4: KANNAN RAJ returned 137,095 units of Common Stock to the company, closing all direct ownership in the company4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4 filed by Geesaman Bard4 - CHIASMA, INC (0001339469) (Issuer)
- INSIDERSEC Form 4 filed by Chiasma, Inc.4 - CHIASMA, INC (0001339469) (Issuer)
CHMA FAQ
7 questionsWhat does Chiasma, Inc. do?
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with...What is the latest news on CHMA?
Quantisnow has not tracked any new filings, ratings or press releases for CHMA in the last 30 days. The most recent wire item was published on November 3, 2022.Where does CHMA stock trade?
Chiasma, Inc. (CHMA) is listed on NASDAQ.What sector and industry is CHMA in?
Chiasma, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Chiasma, Inc. go public?
Chiasma, Inc. (CHMA) completed its IPO in 2015.What companies are similar to CHMA?
Notable peers in the same industry include ADMS (Adamas Pharmaceuticals, Inc.), ADRO (Aduro Biotech, Inc.), ADXS (Advaxis, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), AIMT (Aimmune Therapeutics, Inc.). Compare CHMA side-by-side with any of them on Quantisnow.How can I track CHMA on Quantisnow?
Quantisnow aggregates Chiasma, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CHMA to receive live email and push alerts on every new disclosure.